Syncona's Nightstar Begins NSR-REP1 Trial And Appoints New Director

5th Mar 2018 13:07

LONDON (Alliance News) - Healthcare-focused investment company Syncona Ltd said on Monday that portfolio company Nightstar Therapeutics PLC has initiated a STAR Phase Three registrational trial to study NSR-REP1 in patients with choroideremia.

The trial is expected to enrol 140 patients across 18 sites in Europe, the US and Canada and South America.

Choroideremia is a rare disease leading to total blindness for which there is currently no treatment.

The primary endpoint of the trial is the number of patients with an improvement of at least 15 Early Treatment Diabetic Retinopathy Study letters from baseline in visual acuity at 12 months after treatment.

In addition, Syncona has appointed Gian Piero Reverberi as non-executive director with effect on April 1.

Reverberi is currently senior vice president and chief commercial officer for NASDAQ-listed pharmaceutical company Vanda Pharmaceuticals Inc, a role he has held for more than two years since December 2015. He previously held roles at Ireland's Shire PLC and the US's Eli Lilly & Co.

"We welcome Gian Piero as a non-executive director to the board of Syncona. His deep experience and strong track record across multiple therapy areas, geographies and in new product launches will be a valuable resource at this exciting time for Syncona, as we see our strategy of building global leaders in life science gather pace," said Chairman Jeremy Tigue.

Shares in Syncona were up 0.6% at 197.00 pence on Monday.

---

Related Shares:

ShireSyncona